Abstract
Effects of Latilactobacillus sakei ADM14 on changes in lipid metabolism and fecal microbiota composition were studied in high-fat diet (HFD) mouse model. The mice were divided into three groups: normal diet (ND), high-fat diet (HD), and HFD plus L. sakei ADM14 (HDA). Oral administration of L. sakei ADM14 daily for 10weeks decreased body weight gain, fat tissue mass, and liver weight in mice and reduced the size of histologically stained liver adipocytes. In addition, serum total cholesterol, triglycerides, and blood glucose decreased significantly. Latilactobacillus sakei ADM14 regulated the expression of genes related to lipid metabolism in epididymal adipose tissue and liver and induced changes in the composition of fecal microbiota, thereby improving energy harvests and changing metabolic disorder-related taxa. A significant decrease (p<0.05) in the Firmicutes to Bacteroidetes ratio was found in the HDA group compared to the HD group, particularly due to the difference in the relative abundance of the Bacteroidetes between the two groups over 10weeks. Differences in proportions of some taxa reported to have correlation with obesity were also found between HD and HDA groups. These results suggest that L. sakei ADM14 can have a positive effect on metabolic disorders such as obesity and fatty liver through effective regulation of host lipid metabolism and gut microbiota.
Highlights
Obesity has emerged as an important health problem through a rapid increase in incidence worldwide
The food efficiency ratio (FER) increased significantly (p < 0.01) in high-fat diet (HD) compared to normal diet (ND), but there was no significant difference despite a 12.9% decrease in HFD plus L. sakei ADM14 (HDA) compared to HD (Figure 1C)
There was a significant decrease of 44.5% in epididymal fat (p < 0.01) and 33.8% in subcutaneous fat (p < 0.05) in HDA compared to HD (Figure 1D)
Summary
Obesity has emerged as an important health problem through a rapid increase in incidence worldwide. Effects of Latilactobacillus sakei ADM14 on Lipid Metabolism nonalcoholic fatty liver disease (NAFLD) has received a lot of attention. A link between the effects of choline deficiency on fatty liver development and changes in the human gut microbiota was confirmed (Spencer et al, 2012), and it was revealed that changes in the gut microbiota regulate the progression of NAFLD (Buzzetti et al, 2016). The regulation of gut microbial communities may suggest new therapeutic strategies in the management of metabolic diseases such as obesity and NAFLD. Probiotics regulate the gut microbiome and have proven beneficial effects on metabolic symptoms. They are known to be effective in improving lipid profiles and hyperlipidemia, while affecting lipid metabolism (Roller et al, 2004; Sun and Buys, 2015)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
